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Vascular endothelial growth factor (VEGF) and its receptors have
been implicated as key factors in tumor angiogenesis that are
up-regulated by hypoxia. We evaluated the effects of DNA-binding
small molecules on hypoxia-inducible transcription of VEGF. A
synthetic pyrrole-imidazole polyamide designed to bind the hyp-
oxia response element (HRE) was found to disrupt hypoxia-induc-
ible factor (HIF) binding to HRE. In cultured HeLa cells, this resulted
in a reduction of VEGF mRNA and secreted protein levels. The
observed effects were polyamide-specific and dose-dependent.
Analysis of genome-wide effects of the HRE-specific polyamide
revealed that a number of hypoxia-inducible genes were down-
regulated. Pathway-based regulation of hypoxia-inducible gene
expression with DNA-binding small molecules may represent a
new approach for targeting angiogenesis.
gene regulation  hypoxia-inducible factor  polyamide
Angiogenesis, the induction of new blood vessels, is critical forgrowth and metastatic spread of solid tumors. It is tightly
controlled by a number of specific mitogenic factors, among
which vascular endothelial growth factor (VEGF) and its re-
ceptors play a central role. The levels of VEGF are up-regulated
across a broad range of tumors and are involved in key aspects
of cancer biology. A hallmark of many cancers, chronic hypoxia,
in conjunction with activation of certain oncogenic signaling
pathways, is responsible for the elevated levels of VEGF and is
associated with invasion and altered energy metabolism (1).
In cells and tissues, hypoxia triggers a multifaceted adaptive
response that is primarily driven by the heterodimeric hypoxia-
inducible factor 1 (HIF-1) (2). Under normal dioxygen levels, the
-subunit of HIF-1 is successively hydroxylated at proline resi-
due 564 (3), ubiquitinated, and then degraded by the ubiquitin–
proteosome system. This process, mediated by the von Hippel–
Lindau tumor suppressor protein (4), is responsible for
controlling levels of HIF-1 and, as a result, the transcriptional
response to hypoxia (5). Under hypoxic conditions, HIF-1
avoids hydroxylation and accumulates. Heterodimerization with
its constitutively expressed binding partner, aryl hydrocarbon
receptor nuclear translocator (ARNT) (6) and binding to a
cognate hypoxia response element (HRE) (7) recruits the
p300CBP and SRC-1 family coactivators, which drive the
expression of hypoxia-inducible genes. Among these are genes
encoding angiogenic peptides such as VEGF and the platelet-
derived growth factor B chain, as well as proteins involved in
glucose metabolism, such as the glucose transporter GLUT1 (8,
9). Inhibition of VEGF, a downstream target of HIF, is sufficient
to inhibit tumor growth in model systems (10).
We designed a sequence-specific DNA-binding molecule to
inhibit binding of the HIF-1ARNT heterodimer to its cognate
DNA sequence to down-regulate the expression of VEGF and
other hypoxia-inducible genes. Because interaction of HIF with
its cognate DNA sequence and subsequent transcriptional acti-
vation is a likely point of significant amplification of response,
disruption of this interaction could represent a point of inter-
vention in the hypoxia response pathway involving multiple
genes.
To regulate the expression of endogenous genes, DNA-
binding small molecules must permeate the cell, localize in the
nucleus (11, 12), access chromatin (13–15), and bind DNA
sequences with affinities and specificities sufficient to disrupt
key regulatory proteins bound to genomic DNA (16–18). Syn-
thetic oligomers containing N-methylpyrrole and N-methylimi-
dazole amino acids conjugated to a fluorescein dye represent a
modular molecular recognition toolkit with properties that
satisfy these criteria. DNA sequence specificity is programmed
by a simple code created by pairs of aromatic rings (19–22).
Although the VEGF gene encodes multiple splicing variants,
analysis of its promoter revealed that a single HRE is located at
nucleotide positions 947 to 939 (5-TACGTG-3) relative to
the common transcription start site (Fig. 1) (23). We designed
polyamide 1 to bind to the DNA sequence 5-WTWCGW-3
(whereWAor T) that encompasses theHRE site in theVEGF
promoter according to the pairing rules (Figs. 1 and 2). A
mismatch control polyamide 2, directed against an unrelated
sequence 5-WGGWCW-3, was also synthesized.
Materials and Methods
Synthesis of Polyamides. Polyamides 1 and 2 were synthesized by
solid-phase methods on Kaiser oxime resin (Nova Biochem) (24)
and conjugated to FITC isomer I (11). The purity and identity
of the polyamide-dye conjugates were verified by analytical
HPLC, UV-visible spectroscopy, and MALDI-ToF MS.
Determination of DNA-Binding Affinities and Sequence Specificities.
A 5 32P-labeled fragment was generated by PCR amplification
of the site from the plasmid pGL2-VEGF-Luc by using primers
5-CTC AGT TCC CTG GCA ACA TCT-3 (VEGFP1) and
5-TGG CAC CAA GTT TGT GGA GCT-3 (VEGFP2) and
isolated by nondenaturing gel electrophoresis (25). Quantitative
DNase I footprint titration experiments were used to determine
the binding affinities and specificities of polyamides 1 and 2 (25).
EMSA. The HIF1ARNT heterodimer was transcribed
translated in vitro by using Promega TNT kit according to the
manufacturer’s instructions. The double-strand oligonucleotide
probe was prepared by annealing the two complementary
strands 5-GAC TCC ACA GTG CAT ACG TGG GCT CCA
ACA GGT-3 (HRE-EMSA1) and 5-ACC TGT TGG AGC
CCA CGT ATG CAC TGT GGA GTC-3 (HRE-EMSA2).
Abbreviations: HIF, hypoxia-inducible factor; ARNT, aryl hydrocarbon receptor nuclear
translocator; HRE, hypoxia response element; DFO, desferrioxamine mesylate; ET,
endothelin.
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Before annealing, the HRE-EMSA1 oligonucleotide was 5-end
radiolabeled with -32-P-ATP (NEN) and T4 polynucleotide
kinase, as described. The radiolabeled double-strand oligonu-
cleotide probe was isolated by using a G25 Quickspin column
(Boehringer Mannheim).
Polyamides were preincubated with the radiolabeled oligonu-
cleotide in Z-buffer (100 mM KCl25 mM Tris, pH 7.50.2 mM
EDTA20% glycerol0.25 mg/ml BSA0.05% Nonidet P-405
mMDTT0.1 mg/ml PMSF1.2 mM sodium vanadate) at 0°C for
30 min. Then the in vitro transcribedtranslated protein mixture,
diluted with the same buffer, was added, and the mixture was
held on ice for an additional 30 min. Each time, the following
controls were included: free oligonucleotide probe, probe with
unprogrammed in vitro transcriptiontranslation reaction mix-
ture, and 100-fold excess of competing nonradiolabeled probe.
The complexes were resolved on a 4% nondenaturing polyacryl-
amide gel and visualized with the Storm 820 Phosphorimager
(Molecular Dynamics).
Cell Culture. The human cervical epithelial adenocarcinoma cell
line HeLa (ATCC CCL-2) was maintained in DMEM as rec-
ommended by American Type Culture Collection. Cell growth
and morphology were monitored by phase-contrast microscopy.
Confocal Microscopy. HeLa cells were trypsinized for 5–10 min at
37°C, centrifuged for 5 min at 2,000 rpm and 5°C in a Beckman
Coulter Allegra 6R centrifuge, and resuspended in freshmedium
to a concentration of 1.25  106 cells per milliliter. Incubations
were performed by adding 150 l of cells into culture dishes
equipped with glass bottoms for direct imaging (MatTek, Ash-
land, MA). The cells were grown in the glass-bottom culture
dishes for 24 h. Themediumwas then removed and replaced with
142.5 l of fresh medium. Then 7.5 l of the 100 M polyamide
solution was added, and the cells were incubated in a 5% CO2
atmosphere at 37°C for 10–14 h. Imaging was performed on a
Zeiss LSM 5 Pascal inverted laser scanningmicroscope equipped
with a 40 oil-immersion objective lens. Analysis of images was
performed as described (11).
Determination of the Relative mRNA and Protein Levels. RNA isolation.
HeLa cells were plated in six-well dishes at a density of 6  105
in 1 ml of DMEM and allowed to attach for 16–20 h. Polyamides
were added, and the cells were incubated for 48 h. The hypoxia
conditions necessary for VEGF induction were created by incu-
bation with 300 M desferrioxamine mesylate (DFO) for 16–18
h (26, 27). Optionally, cells were tested for apoptosis by staining
with annexin V. The medium was removed, and cells were
washed with ice-cold PBS and immediately lysed with RLT
buffer from the RNeasy kit (Qiagen, Chatsworth, CA) with
2-mercaptoethanol added. Further RNA isolation was carried
out with the RNeasy kit as described in the manufacturer’s
manual. The isolated total RNA was quantified. The yields were
12–15 g per well. Genomic DNA was digested by treatment
with DNase I from a DNA Free kit (Ambion, Austin, TX), and
DNase I was inactivated with bead-immobilized DNase I inac-
tivation reagent (Ambion).
Reverse transcription. A 2.5-g sample of total RNA was used to
reverse-transcribe cDNA by using Powerscript II reverse tran-
scriptase (BD Clontech) according to the manufacturer’s pro-
tocol. Random hexamers and oligo-(dT)16 primers were used
simultaneously in a 1:1 ratio. The total volume for each reverse
transcription reaction was 20 l.
Real-time quantitative RT-PCR analysis. Real-time quantitative RT-
PCR analysis was performed by using the VEGF gene primers
described below. The forward primer 5-AGG CCA GCA CAT
AGG AGA GA-3 and reverse primer 5-TTT CCC TTT CCT
CGA ACT GA-3 were used to amplify the 104-bp fragment
from the 3-translated region of VEGF. RNA was standardized
by quantification of the -glucuronidase gene as an endogenous
control (28). The forward primer 5-CTC ATT TGG AAT TTT
GCCGAT T and reverse primer 5- CCGAGTGAAGATCCC
CTT TTT A were used for this gene (29). Quantitative real-time
RT-PCR was performed by using Applied Biosystems SYBR
Green RT-PCR master mix according to the manufacturer’s
instructions. Temperature cycling and detection of the SYBR
green emission were performed with an ABI 7300 real-time
instrument by using Applied Biosystems Sequence Detection
System, Version 1.2. Statistical analysis was performed on three
independent experiments.
VEGF ELISA. Approximately 105 HeLa cells were split into 24-well
plates. After 24 h, the cells were incubated with polyamides 1 or
2 (0.2 or 1 M) for 32 h. Fresh polyamide was added followed
by addition of DFO (300 M) and further incubation for 16 h.
The supernatant (100 l) was used for the VEGF ELISA (R &
D Systems), which was carried out according to the manufac-
turer’s instructions.
Analysis of Gene Expression with Oligonucleotide Microarrays. Ex-
periments were carried out at the Caltech Genome Expression
Fig. 1. Map of the VEGF promoter with the HRE site (Upper) and schematic
representation of match polyamide 1 targeting the HRE and mismatch poly-
amide 2 designed for this study (Lower). Imidazole and pyrrole rings are
represented as solid and open circles, respectively; 3-chlorothiophene is de-
picted as a square, and aliphatic linkers as curved lines. Half-diamonds with
plus signs represent 3,3-diamino-N-methyldipropylamine. FITC represents
conjugated FITC (isomer I).
Fig. 2. Structures of the polyamide–FITC conjugates 1 and 2.








Center. HeLa cells were split and plated in a manner similar to
that in the RT-PCR experiments. Cultured cells were incubated
for 48 h with 0.2 or 1 M polyamide 1 or 2. Hypoxic conditions
were induced by adding DFO to a final concentration of 300 M.
The cells were incubated with DFO for 12 h, and total RNA was
collected as described for the RT-PCR experiments. After
testing for quantity and quality, the total RNA was subjected to
the Affymetrix protocols. Affymetrix GenechipHumanGenome
U133A microarrays were used in each experiment. The exper-
iments were carried out in triplicate. Correlation between the
replicates was 0.970. The data were analyzed with RESOLVER,
Ver. 3.0 (Rosetta Biosoftware, Seattle).
Results
Binding Affinities and Specificities. Based on the pairing rules,
match polyamide 1 targets sequences of the type 5-WTWCGW
-3 (where W  A or T), whereas mismatch polyamide 2 targets
sequences of the type 5-WGGWCW-3. The 3-chlorothiophene
ring at the N terminus of polyamide 1 provides specificity for a
T•A base pair (22). We mapped the detailed binding sites for
both match and mismatch polyamides on the VEGF promoter
fragment that encompasses the HRE. From DNase I footprint
titrations, a Ka value of 6.3  109 M1 was obtained for
polyamide 1 at the HRE site (Fig. 3A). The mismatch polyamide
2 bound the HRE site with100-fold lower affinity (Ka 7.9
107M1). Nomatch sites at 1.0 nM concentration could be found
for polyamide 2 in the region of this DNA that can be resolved
by gel electrophoresis.
Disruption of the HIF–DNA Complex. We tested the ability of
polyamides to inhibit the binding of HIF-1ARNTheterodimer
to the HRE in an EMSA. The radiolabeled DNA fragment (24
bp) was first incubated with match or mismatch polyamide 1 or
2, respectively. After the subsequent addition of the in vitro
translated HIF-1ARNT heterodimer, the resulting complexes
were resolved on a nondenaturing polyacrylamide gel. Match
polyamide 1 (0.25 nM) effectively inhibited binding of the
heterodimer, whereas much less effect was observed for the
mismatch polyamide 2 at concentrations as high as 2.5 M (Fig.
3B). See also Fig. 7, which is published as supporting information
on the PNAS web site.
Uptake of Polyamides in Cultured HeLa Cells. The uptake of both
polyamides by the HeLa cell line was examined by laser-scanning
confocal microscopy. Previous studies indicated that the degree
of cellular uptake and nuclear localization of polyamides con-
taining an eight-ring sequence recognition core depends on the
pyrroleimidazole content of the core and varies for each cell
line (11, 12). We find that both polyamides exhibit strong nuclear
localization after incubation at 2 M concentration for 12 h at
37°C in standard culture medium (Fig. 4).
Effect of Polyamides on Cell Viability and Growth Rate.Weexamined
whether prolonged incubation with polyamides affects cell via-
bility. HeLa cells were incubated with polyamides at 1 M
concentration, trypsinized and counted at various time points
(0–72 h) by using a hemocytometer. Measurements of cell
growth rates indicate that polyamides at 1 M in standard
culture medium have no deleterious effects on cell growth and
division (see Fig. 8, which is published as supporting information
on the PNAS web site).
Analysis of Promoter Activity with Luciferase Assays.We used HeLa
cells that had been stably transfected with a reporter plasmid
VEGF-Luc containing the VEGF promoter upstream of lucif-
Fig. 3. Polyamide 1 binds HRE. (A) Storage phosphor autoradiograms from
quantitative DNase I footprint titrations of polyamides 1 and 2. The boxed
sequence (Left) represents the HRE site. For polyamide 1, lanes 1 and 16, A
reaction: lane 2, intact DNA; lanes 3–14, DNase I digestion products in the
presence of 50 nM, 20 nM, 10 nM, 5 nM, 2 nM, 1 nM, 500 pM, 200 pM, 100 pM,
50 pM, 20 pM, and 10 pM polyamide, respectively; lane 15, DNase I standard.
For polyamide 2, lanes 1 and 16, A reaction: lane 2, intact DNA; lanes 3–14,
DNase I digestion products in the presence of 1 M, 300 nM, 100 nM, 30 nM,
10 nM, 3 nM, 1 nM, 300 pM, 100 pM, 30 pM, 10 pM, and 3 pM polyamide,
respectively; lane 15, DNase I standard. (B) Storage phosphor autoradiogram
from EMSA experiment with polyamides 1 and 2.
Fig. 4. Cellular localization of polyamides 1 (A andB) and 2 (C andD ) in HeLa
cells. (A and C) Fluorescence signals from polyamides. (B and D) Overlays of
fluorescence signals with visible light images.
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erase CDNA. The experiments were carried out in a hypoxic
chamber with 1% O2 to mimic closely the conditions of physi-
ological hypoxia. Incubation with the match polyamide 1 re-
sulted in a decrease of promoter activity in a dose-dependent
manner, as indicated by decreased levels of luciferase activity. A
negligibly small effect was observed for mismatch polyamide 2
(Fig. 9, which is published as supporting information on the
PNAS web site).
As a specificity control, we constructed and used in parallel a
nearly identical reporter VEGF-M1Luc where the HRE and
surrounding sequences had been mutated to disfavor binding of
HIF-1 (Fig. 10, which is published as supporting information on
the PNAS web site). In these experiments and those that follow,
the hypoxia mimetic compound DFO (26, 27) was used to
stabilize HIF and activate HIF target genes. Cells were harvested
after incubation with 300 M DFO for 12–16 h.
Treatment of stably transfected HeLa cells with match poly-
amide 1 led to significant attenuation of hypoxia-inducible
VEFG-Luc activity. By contrast, treatment with mismatch poly-
amide 2 resulted in only a modest decrease of VEGF-Luc
activity. The VEGF-M1Luc promoter with a mutated HRE site
showed no inducibility under hypoxic conditions. No effect of
polyamides on the levels of luciferase activity in cells transfected
with the mutant promoter was observed (Fig. 10). No obvious
cytotoxicity was observed.
Suppression of Hypoxia-Inducible Transcription in Cultured Cells.We
used real-time quantitative RT-PCR assays to evaluate the
relative levels of VEGF mRNA in hypoxic HeLa cells treated
with polyamides. In parallel, untreated cells were used as con-
trols. Expression of -glucuronidase was used as a control gene
for determining the relative levels of transcription (29). After
48 h of incubation with polyamide 1, levels of VEGF expression
were reduced in a dose-dependent manner (Fig. 5A). Polyamide
1 at 1 M inhibits VEGF expression 60%, which is near the
VEGF mRNA levels in the uninduced (normoxic) cells. Mis-
match polyamide 2 shows minimal inhibition at either 0.2 M or
1 M concentrations.
ELISA was used to determine the levels of secreted VEGF.
Total protein levels were monitored in parallel, to exclude the
possibility of disruption of general transcriptional activity by the
polyamides. Under normoxia, match polyamide 1 caused a
modest decrease of the basal expression levels of VEGF, whereas
mismatch polyamide 2 caused no decrease of VEGF levels.
Under hypoxic conditions, polyamide 1 decreased levels of
VEGF in a dose-dependent manner, whereas mismatch poly-
amide 2 had a minimal effect (Fig. 5B).
Genome-Wide Effects of Polyamides. The effects of polyamide
treatment on nuclear transcription were monitored by global
gene expression analysis by using Affymetrix high-density Uni-
Gene 133A microarrays, which contain oligonucleotide se-
quences representing20,000 annotated genes. HeLa cells were
treated in triplicate with no polyamide, polyamide 1, or poly-
amide 2 at 1 M and 0.2 M concentrations, for 48 h. DFO was
then added to a concentration of 300 M for an additional 12–16
Fig. 5. Polyamide 1 blocks VEGF induction by hyopoxia. (A) Relative mRNA
levels of expression of the VEGF gene as measured by real-time quantitative
RT-PCR. (B) Levels of secreted VEGF protein as measured by ELISA. The final
concentration of polyamides 1 and 2 was 0.2 or 1 M. Noninduced polyamide
concentrations in A were 1 M for each.
Fig. 6. Venn diagrams representing the distribution of affected genes (P 
0.01) from the microarray experiments. The numbers outside the intersections
represent genes uniquely affected by the individual polyamides.








h and total RNA was collected. Purified RNA was treated and
hybridized to the oligonucleotide microarrays according to es-
tablished protocols.
Fig. 6 lists the number of genes affected uniquely and
similarly by polyamides 1 and 2 at 0.2 and 1 M. At each
threshold, there is a majority of genes uniquely affected by
each polyamide, as well as a number of genes similarly affected
by both polyamides. This is consistent with previous work
suggesting that polyamides that target different DNA se-
quences can affect the expression of different sets of genes
(13). At a threshold of 2.0-fold, 264 and 73 genes are down-
regulated and up-regulated, respectively, in the presence of
polyamide 1 at 1 M. This represents only 1.5% of the
interrogated genes. In the case of polyamide 2, 1.0% are
affected at this threshold. These effects are surprising, given
that a polyamide with a 6-bp binding site is expected to have
1.4 million match sites in a 3 billion-base pair genome. Genes
affected at a threshold of 2.0-fold for each polyamide are listed
in Tables 2 and 3, which are published as supporting infor-
mation on the PNAS web site. Polyamides 1 and 2 at 0.2 M
affect the expression of fewer genes at each threshold level as
compared with the 1 Mdata sets. It should be noted that most
genes down- and up-regulated by each polyamide at 0.2 M are
similarly affected in the 1 M data set for each polyamide.
Next, we analyzed differential expression levels of several
hypoxia-inducible genes in the presence of polyamides 1 or 2
(Table 1). The expression of the main target gene, VEGF, is
down-regulated by 1.34-fold with polyamide 1 and virtually
unaltered with polyamide 2. These data parallel the RT-PCR
experiments and luciferase experiments. Other hypoxia-
inducible genes are also affected, albeit to a different extent.
Remarkably, the microarray data indicated significantly down-
regulated levels of the mRNAs corresponding to all three
endothelin (ET) genes. In fact, the levels of ET-2 were 90%
(13.6-fold) down-regulated with polyamide 1 as compared with
the untreated controls. Interestingly, the controls treated with
polyamide 2 show nearly 3-fold down-regulation of ET-2. This
effect was validated by real-time quantitative RT-PCR of ET-2
mRNA levels, where 6.8-fold down-regulation was observed for
polyamide 1 and 2.4-fold for polyamide 2. According to the
microarray data, ET-1 was found to be down-regulated 2.4-fold
by polyamide 1 and 1.26-fold by polyamide 2. Real-time quan-
titative RT-PCR measurements were generally consistent with a
1.5-fold down-regulation of ET-1 mRNA by polyamide 1 and no
detectable down-regulation by polyamide 2. Recent studies
indicate the emerging role of ETs in cancer (30). In addition,
ET-2 has been recently implicated as an autocrine survival factor
in hypoxic cells (31). We will defer a detailed discussion of the
effects of polyamides 1 and 2 on the expression of the ET genes
until a more thorough analysis of their regulation has been
undertaken.
Discussion
The expression of VEGF has received considerable attention
because this potent mitogen can stimulate endothelial cell
proliferation and migration in vitro (32, 33) as well as angiogen-
esis in vivo (34, 35). Elevated VEGF levels are associated with
the progression of a variety of tumors and correlated to the
outcome of cancer treatment (36, 37). To date, numerous
attempts to block the activity of VEGF have been made,
including the use of antibodies (38), soluble VEGF receptors
(39), VEGF receptor antagonists (40), or degradation of the
VEGF message through the use of antisense oligonucleotides
(41) or by RNA interference (42, 43). The major focus of the
previous studies was inhibition of a single target or a very limited
number of targets. This work presents a pathway-specific ap-
proach where the expression of multiple genes is down-regulated
by targeting a common transcription factor-binding site. Because
there is some sequence variation within the consensus HRE
site, we would anticipate that some, but not all, HIF-regulated
genes would be affected by polyamide 1 programmed for 5-
WTWCGW-3.
The details of oncogenic signaling pathways that give rise to
the cancerous cellular phenotype continue to be elucidated.
These signaling pathways involve a large number of proteins
involved in signal transduction that ultimately converge upon
a much smaller set of oncogenic transcription factors (44).
Hence, targeting transcription factors with small molecules
may be the most direct way of reversing the cancerous phe-
notype. Toward this goal, one can use small molecules to target
critical protein–protein interactions between transcription fac-
tors and coactivators (45, 46). DNA-binding polyamides offer
an alternate approach by interfering with protein–DNA inter-
actions. However, selective gene regulation by programmable
DNA-binding polyamides depends on a precise knowledge of
cis-acting promoter elements and the trans-acting factors that
bind them.
Our results indicate that polyamide–FITC conjugate 1, de-
signed to target the HRE, can bind its cognate site with high
affinity and specificity and is capable of disrupting binding of
HIF-1 to HRE. The polyamide–FITC conjugate was localized in
the nuclei of cultured HeLa cells with no deleterious effects on
growth or replication rate. Analysis of the VEGF mRNA levels
by real-time quantitative RT-PCR and secreted levels of VEGF
Table 1. Relative expression levels of selected HIF-inducible genes
GenBank accession no. Annotated gene
Fold change
Polyamide 1 Polyamide 2
1 M 0.2 M 1 M 0.2 M
Energy metabolism
AI761561 Hexokinase-2 1.3 – – –
NM_005165.1 Aldolase-C – – – –
Hormonesreceptors
J03241.1 Transforming growth factor 3 – – – –
Vasoactive proteins
AF022375.1 VEGF 1.35 1.4 – –
NM_002019.1 VEGF receptor, Flt-1 1.5 – – –
NM_001955.1 ET-1 2.4 1.9 1.3 -
NM_001956.1 ET-2 13.2 2.2 2.8 2.0
NM_000114.1 ET-3 1.8 – – –
Fold change  1.2 and P  0.01.
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by ELISA indicated reduction of the promoter activity in hypoxic
cells resulting in the concomitant decrease of VEGF production
to near its basal levels. Analysis of the genome-wide effects of the
polyamide provided further insights into the transcriptional
activity of multiple hypoxia-inducible genes. Because many
biological responses are threshold-based, the overall decrease of
the transcriptional activity to the basal levels could have pro-
nounced downstream effects. Previous studies have shown that
the magnitude of induction of VEGF mRNA in mice subjected
to systemic hypoxia varies with tissue type but generally falls
between 2- and 4-fold, consistent with the levels of induction
measured in this study (47).
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